Hormones (such as prednisone, methylprednisolone, etc.) are a wide range of applications.
A ubiquitous, therapeutically effective drug. But at the same time, due to the complex pharmacological effects, if improperly applied, it will bring various adverse reactions. In principle, a small dose of short course of treatment should be used.
Infection, hypertensive crisis, severe osteoporosis, peptic ulcer with bleeding, glaucoma, diabetes, etc.
The occurrence of hormonal adverse reactions is related to the dose and course of treatment.
Small doses (such as prednisone ≤ 7.5 ~ 10mg / day) generally have no obvious adverse reactions. However, high doses and long courses lead to increased side effects. In addition, it is also related to liver and kidney function, age and so on.
Common adverse reactions:
1. Immune system: increase the chance of infection, neutrophils, mononuclear macrophages and lymphocyte activity decreased.
2. Musculoskeletal system: osteoporosis is easy to fracture, aseptic osteonecrosis, myopathy.
3. Gastrointestinal tract: peptic ulcer, pancreatitis and so on.
4. Cardiovascular system: high blood pressure, water and sodium retention, accelerated atherosclerosis and so on.
5. Skin: acne, purple lines, hairy, skin becomes brittle.
6. Neuropsychiatry: changes in consciousness, mood swings, abnormal behavior, insomnia, etc.
7. Eyes: cataract, glaucoma, etc.
8. Endocrine and metabolic aspects: impaired glucose tolerance, diabetes, weight gain, hyperlipidemia, obesity, growth retardation, wound healing, muscle atrophy, hypokalemia, fatigue, menstrual disorders and acute adrenal crisis.
Hormone drugs, as a drug with rapid and obvious side effects but also serious side effects, have always been controversial. It is generally necessary for hospitals to avoid using the drug as much as possible.
The world-renowned pharmaceutical company Merck recently announced the results of a new clinical study: long-term use of hormonal drugs may slow children's growth and development. The study used a multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to observe 360 patients with mild childhood asthma for 56 weeks. The clinical study was divided into three groups: beclomethasone (hormone drug) group, Montelust sodium (non-hormonal drugs) group and placebo group. After 56 weeks, the growth rate of children's height was calculated as 4.86 cm/year according to the LS mean value. , 5.67 cm / year and 5.64 cm / year. That is, the average height of children taking the beclomethasone group increased by 4.86 cm per year, and the average height of children who took the Montelust sodium group increased by 5.67 cm per year. The average height of children in the placebo group increased by 5.64 cm per year. The result means that children who use hormones have an annual increase of 0.78 to 0.81 cm less than normal children.